With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

Early research shows a one-time gene therapy has potential for addressing both the liver and lung disease that patients with ...

Alpha Bank’s senior leadership met with state officials and key business figures in Cyprus this week, in order to outline its ...

The race for Florida’s 1st Congressional District, the seat former Rep. MATT GAETZ (R-Fla.) vacated for a short-lived ...

Two years into the generative artificial intelligence (GenAI) era, it’s harder than ever for venture capitalists to spot ...

Astronomers have identified a quartet of small rocky planets orbiting Barnard's star, one of our closest stellar neighbours.

KRRO-110 is the first RNA editing development candidate from Korro's proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the ...

Q4 2024 Earnings Call Transcript March 13, 2025 Seres Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, ...

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...